

Ahmet Emre Eskazan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2187799/ahmet-emre-eskazan-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

131
papers

733
citations

15
h-index

20
g-index

158
ext. papers

980
ext. citations

3
avg, IF

4.96
L-index

#	Paper	IF	Citations
131	F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging Appearance of Gastrointestinal Behçet's Disease.. <i>Molecular Imaging and Radionuclide Therapy</i> , 2022 , 31, 57-59	0.8	
130	Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.. <i>Leukemia Research</i> , 2022 , 114, 106808	2.7	3
129	Tackling TKI resistance in AML: A commentary on "Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML." by Yamatani et al.. <i>Translational Oncology</i> , 2022 , 19, 101394	4.9	
128	Is it possible to predict the pCR with CBC? A commentary on "correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer" by Meng et al.. <i>Translational Oncology</i> , 2022 , 20, 101403	4.9	
127	The Impact of the COVID-19 Pandemic on the Diagnosis and Management of Patients with Classical Hodgkin Lymphoma: A Single-Center Experience. <i>Blood</i> , 2021 , 138, 1394-1394	2.2	
126	Treatment Responses, Toxicity and Survival in Patients with Classical Hodgkin Lymphoma Aged 50 Years and Older: A Single-Center Experience over 2 Decades. <i>Blood</i> , 2021 , 138, 4541-4541	2.2	
125	The Impact of EUTOS Long-Term Survival (ELTS) Score on Predicting Progression and Survival Among Turkish Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2021 , 138, 4600-4600	2.2	
124	Novel tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. <i>Expert Review of Hematology</i> , 2021 , 1-4	2.8	5
123	Giant Cell Arteritis with Concomitant Chronic Myelomonocytic Leukemia. <i>Turkish Journal of Haematology</i> , 2021 , 38, 226-227	0.9	
122	Asciminib in chronic myeloid leukemia: many questions still remain to be answered. <i>Blood Cancer Journal</i> , 2021 , 11, 81	7	2
121	Candida esophagitis incidentally detected by 18F-FDG PET/CT in a patient with CNS lymphoma. <i>Clinical Case Reports (discontinued)</i> , 2021 , 9, e04322	0.7	0
120	Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis. <i>Hematology, Transfusion and Cell Therapy</i> , 2021 ,	1.6	
119	COVID-19 presenting with immune thrombocytopenia: A case report and review of the literature. <i>Journal of Medical Virology</i> , 2021 , 93, 43-45	19.7	24
118	Platelet count threshold for lumbar puncture: Does one size really fit all?. <i>Transfusion</i> , 2021 , 61, 329	2.9	
117	The prognostic value of serum levels of a proliferation-inducing ligand (APRIL) in treatment-naïve patients with chronic lymphocytic leukemia. <i>Turkish Journal of Medical Sciences</i> , 2021 , 51, 348-354	2.7	
116	COVID-19 in Chronic-Phase Chronic Myeloid Leukemia Patients: A Single-Center Survey from Turkey. <i>Turkish Journal of Haematology</i> , 2021 , 38, 79-81	0.9	6
115	New kid on the block: C-reactive protein-to-albumin ratio as a new prognostic marker for chronic lymphocytic leukemia: Comment on "C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 cases". <i>Translational Oncology</i> , 2021 , 14, 101898	4.9	

114	Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 549-557	2.5	1
113	Tocilizumab in COVID-19: The Cerrahpaş-PREDICT score. <i>Journal of Infection and Chemotherapy</i> , 2021 , 27, 1329-1335	2.2	6
112	Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs. <i>Blood Advances</i> , 2021 , 5, 3344-3353	7.8	2
111	Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab: COMMENT from Elbazan et al. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2644-2646	15.4	
110	Therapy-related chronic myeloid leukemia in a patient receiving peptide receptor radionuclide therapy for pancreatic neuroendocrine tumor. <i>Cancer Reports</i> , 2020 , 3, e1282	1.5	2
109	Management of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Chronic Myeloid Leukemia: What is the Best Strategy?. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, e237-e238	4.7	
108	Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?. <i>Leukemia</i> , 2020 , 34, 3426-3427	10.7	0
107	Novel therapeutic approaches in chronic myeloid leukemia. <i>Leukemia Research</i> , 2020 , 91, 106337	2.7	15
106	Assessment and Monitoring of Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): Strategies to Improve Outcomes. <i>Journal of Blood Medicine</i> , 2020 , 11, 319-326	2.3	3
105	Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country. <i>Annals of Hematology</i> , 2020 , 99, 2671-2677	3	3
104	Copy-number variations in adult patients with chronic immune thrombocytopenia. <i>Expert Review of Hematology</i> , 2020 , 13, 1277-1287	2.8	0
103	The Impact and Prognostic Significance of Chronic Lymphocytic Leukemia Upregulated 1 (CLLU1) Gene Expression in Patients with Chronic Lymphocytic Leukemia: A Single Center Experience. <i>Laboratory Medicine</i> , 2020 , 51, 259-264	1.6	
102	Follicular lymphoma generating in a patient with non-small cell lung cancer following nivolumab discontinuation. <i>Journal of Oncology Pharmacy Practice</i> , 2020 , 26, 2042-2046	1.7	2
101	Is measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia?. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2094-2095	1.9	0
100	Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 1251-1258	4.4	26
99	An alternative way - tyrosine kinase inhibitor (TKI) de-escalation - to discontinue TKIs in order to achieve treatment-free remission. <i>Expert Review of Hematology</i> , 2019 , 12, 477-480	2.8	2
98	Coexistence of Hermansky-Pudlak syndrome and JAK2-positive essential thrombocythemia. <i>Ultrastructural Pathology</i> , 2019 , 43, 94-98	1.3	
97	The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e377-e384	2	2

96	Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2019 , 60, 200-207	1.9	5
95	Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword. <i>Acta Oncologica</i> , 2019 , 58, 123-124	3.2	
94	Tyrosine kinase inhibitors (TKIs) used in the management of chronic myeloid leukaemia are associated with haematologic toxicities-Which TKI is the safest?. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2241-2243	3.8	4
93	Tyrosine Kinase Inhibitor-Associated Platelet Dysfunction: Does This Need to Have a Significant Clinical Impact?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019 , 25, 1076029619866925	3.3	4
92	The tolerability issue of generic imatinib in patients with chronic myeloid leukemia. <i>Haematologica</i> , 2019 , 104, e330	6.6	1
91	Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e241	2	2
90	New drugs approved for acute myeloid leukaemia in 2018. <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2689-2693	3.8	20
89	PB1929 POTENTIAL DRUG-DRUG INTERACTIONS AMONG PATIENTS WITH CHRONIC MYELOID LEUKEMIA UNDER TYROSINE KINASE INHIBITOR THERAPY WITH IMATINIB. <i>HemaSphere</i> , 2019 , 3, 877	0.3	1
88	Management of Major Surgical Procedures in Patients with Hemophilia: A Single-Center Experience of 49 Procedures. <i>Blood</i> , 2019 , 134, 4933-4933	2.2	
87	The Real-Life Data on the Outcome of Hepatitis B Infection in Patients with B-Cell Lymphoproliferative Neoplasms Treated with Ibrutinib. <i>Blood</i> , 2019 , 134, 4316-4316	2.2	
86	The issue of financial toxicity in the management of chronic myeloid leukemia with blast crisis. <i>Journal of Medical Economics</i> , 2018 , 21, 709-711	2.4	2
85	The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia. <i>Cancer</i> , 2018 , 124, 3806-3818	6.4	15
84	Dasatinib-induced pulmonary arterial hypertension. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 835-845	3.8	28
83	Comment and response to: the significance of early warning in chronic myeloid leukemia. <i>Expert Review of Hematology</i> , 2018 , 11, 267-268	2.8	
82	Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature. <i>Hematology</i> , 2018 , 23, 212-220	2.2	10
81	Cytopenia in adult brucellosis patients. <i>Indian Journal of Medical Research</i> , 2018 , 147, 73-80	2.9	7
80	Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib. <i>International Journal of Clinical Oncology</i> , 2018 , 23, 400-401	4.2	
79	Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single-Institution Experience. <i>Balkan Medical Journal</i> , 2018 , 35, 417-421	1.5	2

78	Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?. <i>Leukemia Research</i> , 2018 , 74, 55-56	2.7	1
77	Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?. <i>Cancer</i> , 2018 , 124, 4260-4261	6.4	1
76	Do all patients with chronic myeloid leukemia need to receive interferon during pregnancy?. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2019-2020	1.9	1
75	Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 325-326	4	
74	Additional chromosomal abnormalities at diagnosis or during tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2516-2517	1.9	
73	Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update. <i>Therapeutic Advances in Hematology</i> , 2017 , 8, 237-243	5.7	16
72	Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors. <i>Turkish Journal of Haematology</i> , 2017 , 34, 233-238	0.9	1
71	Vascular Adverse Events During Long-term Nilotinib Therapy in Patients With Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, e63-e64	2	
70	Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017 , 17, 804-811	2	16
69	Midostaurin in FLT3-Mutated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2017 , 377, 1903-1913	39.2	21
68	Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience. <i>Turkish Journal of Haematology</i> , 2017 , 34, 291-299	0.9	5
67	Comparison of International Prognostic Index and NCCN-IPI in 324 patients with de novo diffuse large B-cell lymphoma: a multi-center retrospective analysis. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1211-4	1.9	4
66	Congenital Dyserythropoietic Anemia Type 1: Report of One Patient and Analysis of Previously Reported Patients Treated with Interferon Alpha. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016 , 32, 272-7	0.7	2
65	Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia. <i>Journal of Clinical Pathology</i> , 2016 , 69, 810-6	3.9	4
64	Pleural tuberculosis in a patient with untreated type 1 Gaucher disease. <i>Journal of Infection and Chemotherapy</i> , 2016 , 22, 53-7	2.2	1
63	Generic imatinib in the treatment of chronic myeloid leukemia: Cerrahpaşa experience. <i>Journal of Oncology Pharmacy Practice</i> , 2016 , 22, 382-4	1.7	1
62	Real-Life Data and a Single Center Experience on the Efficacy and Toxicity Profile of Imatinib in the Treatment of Elderly Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 1905-1905	2.2	
61	The Changing Epidemiology of Bloodstream Infections and Resistance in Hematopoietic Stem Cell Transplantation Recipients. <i>Turkish Journal of Haematology</i> , 2016 , 33, 216-22	0.9	12

60	Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations. <i>Drug Design, Development and Therapy</i> , 2016 , 10, 3355-3361	4.4	19
59	Adverse events of tyrosine kinase inhibitors and their impact on quality of life in patients with chronic myeloid leukemia. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016 , 1, 353-359		9
58	Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in a Developing Country. <i>Clinical Therapeutics</i> , 2016 , 38, 680-1	3.5	
57	Treatment of patients with immune thrombocytopenia admitted to the emergency room. <i>International Journal of Hematology</i> , 2016 , 104, 216-22	2.3	6
56	Bortezomib therapy in patients with relapsed/refractory acquired thrombotic thrombocytopenic purpura. <i>Annals of Hematology</i> , 2016 , 95, 1751-6	3	31
55	Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting. <i>European Journal of Clinical Pharmacology</i> , 2016 , 72, 1537-1538	2.8	
54	Radotinib in the treatment of chronic phase chronic myeloid leukemia patients. <i>Haematologica</i> , 2015 , 100, e39	6.6	5
53	The current situation and future aspects of cost-effectiveness in chronic myeloid leukemia treatment. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1554-5	1.9	1
52	The efficacy and tolerability issue of generics of imatinib in the treatment of chronic myeloid leukemia: do generics really jeopardize patient safety?. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1182-3	1.9	2
51	Postoperative thrombotic thrombocytopenic purpura. <i>Surgery Today</i> , 2015 , 45, 8-16	3	10
50	Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode. <i>Turkish Journal of Haematology</i> , 2015 , 32, 243-50	0.9	6
49	Relapse after allogeneic hematopoietic stem cell transplant in patients with chronic myeloid leukemia: tyrosine kinase inhibitors, donor lymphocyte infusions or both?. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2995-6	1.9	4
48	Real-Life Data and a Single Center Experience on Dasatinib-Induced Pulmonary Arterial Hypertension in Patients with Philadelphia Chromosome-Positive Leukemias. <i>Blood</i> , 2015 , 126, 4037-4037 ^{2,2}		3
47	The Treatment of Chronic Myeloid Leukaemia (CML) in the Era of Tyrosine Kinase Inhibitors [What is New in the Battle of CML?]. <i>European Oncology and Haematology</i> , 2015 , 11, 30	0.1	2
46	Second primary malignancies in chronic myeloid leukemia patients. <i>Journal of Cancer Research and Therapeutics</i> , 2015 , 11, 1042	1.2	
45	Can Positron Emission Tomography and Computed Tomography Be a Substitute for Bone Marrow Biopsy in Detection of Bone Marrow Involvement in Patients with Hodgkin's or Non-Hodgkin's Lymphoma?. <i>Turkish Journal of Haematology</i> , 2015 , 32, 213-9	0.9	3
44	Imatinib Mesylate Reduces Bone Marrow Fibrosis and Overwhelms the Adverse Prognostic Impact of Reticulin Formation in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 2783-2783	2.2	1
43	Posttransplant Secondary Neoplasms: A Single Center Experience. <i>Blood</i> , 2015 , 126, 5485-5485	2.2	

42	Haemophilic Arthropathy Is a Risk Factor for Reduced Bone Mineral Density and Vitamin D Deficiency. <i>Blood</i> , 2015 , 126, 4685-4685	2.2	
41	New CNV Regions Identified in ITP Provide Evidence for Genetic Predisposition. <i>Blood</i> , 2015 , 126, 77-77	2.2	
40	The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2935-7	1.9	11
39	First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate. <i>British Journal of Haematology</i> , 2014 , 167, 139-41	4.5	15
38	Two cases of autoimmune hemolytic anemia secondary to brucellosis: a review of hemolytic disorders in patients with brucellosis. <i>Internal Medicine</i> , 2014 , 53, 1153-8	1.1	13
37	Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. <i>Turkish Journal of Haematology</i> , 2014 , 31, 374-80	0.9	2
36	Spondylodiscitis: evaluation of patients in a tertiary hospital. <i>Journal of Infection in Developing Countries</i> , 2014 , 8, 1272-6	2.3	20
35	Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion. <i>Leukemia Research</i> , 2014 , 38, 781-7	2.7	24
34	Bone marrow transplantation for Behçet's disease: a case report and systematic review of the literature. <i>Rheumatology</i> , 2014 , 53, 1136-41	3.9	29
33	Acute colitis presenting with hematochezia in a patient with chronic myeloid leukemia during dasatinib therapy. <i>Turkish Journal of Gastroenterology</i> , 2014 , 25 Suppl 1, 233	1	6
32	The Prognostic Value of Serum APRIL Levels in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2014 , 124, 5648-5648	2.2	
31	Successful management of chronic refractory immune thrombocytopenia with laparoscopic splenectomy in a patient with acute promyelocytic leukemia. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2013 , 29, 173-7	0.7	2
30	Brucellar pericarditis: a report of four cases and review of the literature. <i>International Journal of Infectious Diseases</i> , 2013 , 17, e428-32	10.5	8
29	Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia. <i>Turkish Journal of Haematology</i> , 2013 , 30, 211-3	0.9	22
28	Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients. <i>Turkish Journal of Haematology</i> , 2013 , 30, 351-8	0.9	10
27	Simultaneous detection of B-cell chronic lymphocytic leukemia and colon adenocarcinoma in the same mesenteric lymph node. <i>Turkish Journal of Haematology</i> , 2013 , 30, 98-9	0.9	1
26	Acute Acalculous Cholecystitis due to Viral Hepatitis A. <i>Case Reports in Infectious Diseases</i> , 2013 , 2013, 407182	0.9	13
25	Detailed analysis of diffuse large B cell lymphoma patients: a single-center, retrospective study. <i>ISRN Hematology</i> , 2013 , 2013, 908191		6

24	Cyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literature. <i>Transfusion</i> , 2013 , 53, 1586-93	2.9	11
23	Interstitial pneumonitis in a patient with chronic myeloid leukemia. <i>Turkish Journal of Haematology</i> , 2013 , 30, 435-6	0.9	1
22	Next-Generation Sequencing Of The BCR-ABL1 Kinase Domain May Be Beneficial In Decision Making Among Chronic Myeloid Leukemia Patients With Tyrosine Kinase Inhibitor Resistance. <i>Blood</i> , 2013 , 122, 384-384	2.2	1
21	Intracranial extramedullary hematopoiesis in patients with thalassemia: a case report and review of the literature. <i>Transfusion</i> , 2012 , 52, 1715-20	2.9	13
20	Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm. <i>Annals of Hematology</i> , 2012 , 91, 305-6	3	3
19	Breast schwannoma in a patient with diffuse large B-cell lymphoma: a case report. <i>Journal of Medical Case Reports</i> , 2012 , 6, 423	1.2	
18	Thrombotic thrombocytopenic purpura after prophylactic cefuroxime axetil administered in relation to a liposuction procedure. <i>Aesthetic Plastic Surgery</i> , 2012 , 36, 464-7	2	2
17	The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms. <i>Turkish Journal of Haematology</i> , 2012 , 29, 242-7	0.9	
16	Hypereosinophilic syndrome associated with simultaneous intracardiac thrombi, cerebral thromboembolism and pulmonary embolism. <i>Internal Medicine</i> , 2012 , 51, 309-13	1.1	6
15	Essential thrombocythemia and multiple myeloma: two rare diseases in one patient. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 442-5	2	8
14	Intracranial mass in a patient with thalassaemia major. <i>British Journal of Haematology</i> , 2011 , 152, 126	4.5	2
13	Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: is that true for all the patients?. <i>Leukemia Research</i> , 2011 , 35, e145-6	2.7	3
12	Variant Philadelphia translocations with different breakpoints in six chronic myeloid leukemia patients. <i>Turkish Journal of Haematology</i> , 2011 , 28, 186-92	0.9	3
11	Primary gastrointestinal diffuse large B cell lymphoma presenting with cold agglutinin disease. <i>Case Reports in Gastroenterology</i> , 2011 , 5, 262-6	1	8
10	Synchronous Detection of Hairy Cell Leukemia and HIV-Negative Kaposi's Sarcoma of the Lymph Node: A Diagnostic Challenge and a Rare Coincidence. <i>Case Reports in Oncology</i> , 2011 , 4, 439-44	1	3
9	Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy. <i>Haematologica</i> , 2011 , 96, e15; author reply e16-7	6.6	16
8	ABL gene kinase domain mutation scanning by denaturing high performance liquid chromatography sequencing method. <i>Turkish Journal of Haematology</i> , 2011 , 28, 97-102	0.9	4
7	Multidrug Resistance Gene (MDR1) C3435T Polymorphism and Imatinib Response in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2011 , 118, 1692-1692	2.2	2

6	Ten-Year Follow-up Data of Diffuse Large B-Cell Lymphoma Patients: Single Center Experience. <i>Blood</i> , 2011 , 118, 5223-5223	2.2	
5	CLLU1 Gene Expression Level As a Prognostic Parameter in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011 , 118, 4603-4603	2.2	
4	Imatinib for Chronic Myeloid Leukemia Patients: A Single Institution Experience. <i>Blood</i> , 2011 , 118, 4429-4429		
3	Sarcoidosis mimicking lymphoma on positron emission tomography-computed tomography in two patients treated for lymphoma: two case reports. <i>Journal of Medical Case Reports</i> , 2009 , 3, 7306	1.2	7
2	Cytogenetic Clonal Evolution in Patients with Chronic Myeloid Leukemia. <i>Biotechnology and Biotechnological Equipment</i> , 2009 , 23, 1515-1520	1.6	2
1	Primary cutaneous immunocytoma/marginal zone B-cell lymphoma: a case with unusual course. <i>American Journal of Dermatopathology</i> , 2004 , 26, 119-22	0.9	9